van Leeuwen RWF - Search Results

1

Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis.

Zietse M, Kooijman T, Malmberg R, Spierings LEAMM, Jager A, Mathijssen RHJ, van Leeuwen RWF, Thielen FW. Zietse M, et al. Among authors: van leeuwen rwf. JCO Oncol Pract. 2025 Jun 4:OP2500482. doi: 10.1200/OP-25-00482. Online ahead of print. JCO Oncol Pract. 2025. PMID: 40466021 No abstract available.

2

Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. van Leeuwen RW, et al. Lancet Oncol. 2014 Jul;15(8):e315-26. doi: 10.1016/S1470-2045(13)70579-5. Lancet Oncol. 2014. PMID: 24988935 Review.

3

Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply.

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. van Leeuwen RW, et al. Lancet Oncol. 2014 Oct;15(11):e470-1. doi: 10.1016/S1470-2045(14)70459-0. Lancet Oncol. 2014. PMID: 25281462 No abstract available.

4

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.

Hussaarts KGAM, van Leeuwen RWF, Mathijssen RHJ. Hussaarts KGAM, et al. Among authors: van leeuwen rwf. JAMA Oncol. 2018 Feb 1;4(2):263-264. doi: 10.1001/jamaoncol.2016.7019. JAMA Oncol. 2018. PMID: 29098281 No abstract available.

5

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.

Hussaarts KGAM, Hurkmans DP, Oomen-de Hoop E, van Harten LJ, Berghuis S, van Alphen RJ, Spierings LEA, van Rossum-Schornagel QC, Vastbinder MB, van Schaik RHN, van Gelder T, Jager A, van Leeuwen RWF, Mathijssen RHJ. Hussaarts KGAM, et al. Among authors: van leeuwen rwf, van gelder t, van alphen rj, van schaik rhn, van harten lj, van rossum schornagel qc. Cancers (Basel). 2019 Mar 22;11(3):403. doi: 10.3390/cancers11030403. Cancers (Basel). 2019. PMID: 30909366 Free PMC article.

6

The added value of H₂ antagonists in premedication regimens during paclitaxel treatment.

Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PMLA, Boere IA, Jager A, Mathijssen RHJ, van Leeuwen RWF. Cox JM, et al. Among authors: van leeuwen rwf, van doorn l, van den bemt pmla. Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.

7

Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab.

Malmberg R, Zietse M, Dumoulin DW, Hendrikx JJMA, Aerts JGJV, van der Veldt AAM, Koch BCP, Sleijfer S, van Leeuwen RWF. Malmberg R, et al. Among authors: van leeuwen rwf, van der veldt aam. Lancet Oncol. 2022 Dec;23(12):e552-e561. doi: 10.1016/S1470-2045(22)00554-X. Lancet Oncol. 2022. PMID: 36455584 Review.

8

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.

Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, Uyl-de Groot CA. Heine RJSD, et al. Among authors: van leeuwen rwf. PLoS One. 2024 Feb 1;19(2):e0293264. doi: 10.1371/journal.pone.0293264. eCollection 2024. PLoS One. 2024. PMID: 38300937 Free PMC article.

9

Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study.

Malmberg R, van Doorn L, Cox JM, Daloul A, Ettafahi H, Oomen-de Hoop E, Zietse M, Bos MEMM, Koch BCP, van Leeuwen RWF. Malmberg R, et al. Among authors: van leeuwen rwf, van doorn l. JCO Oncol Pract. 2024 Sep;20(9):1243-1251. doi: 10.1200/OP.24.00110. Epub 2024 Jun 7. JCO Oncol Pract. 2024. PMID: 38848522

10

Interchangeability of immune checkpoint inhibitors: an urgent need for action.

Zietse M, van Leeuwen RWF, Barjesteh van Waalwijk van Doorn-Khosrovani S, de Boer JE, Dupree R, Mathijssen RHJ, Timmers L. Zietse M, et al. Among authors: van leeuwen rwf. Lancet Oncol. 2024 Nov;25(11):e611-e616. doi: 10.1016/S1470-2045(24)00212-2. Epub 2024 Oct 14. Lancet Oncol. 2024. PMID: 39419062 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters